Lonsurf® (trifluridine/tipiracil) – Expanded indication
August 3, 2023 - Taiho Oncology and Taiho Pharmaceutical announced the FDA approval of Lonsurf (trifluridine/tipiracil), as a single agent or in combination with bevacizumab, for the treatment of adult patients with metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.
Top